# REPORT OF THE NCAA DIVISION III INTERPRETATIONS AND LEGISLATION COMMITTEE

## ***ACTION ITEMS***

**1. Legislative.**

- **None.**

**2. Nonlegislative.**

- **None.**

## ***INFORMATIONAL ITEMS***

**1. Approval of Staff Interpretation**. The NCAA Division III Interpretations and Legislation Committee reviewed a staff interpretation [Reference: 10/26/11, Item Ref. c] issued in Division III incorporating the NCAA Executive Committee policy regarding transgender student-athlete participation in intercollegiate athletics. The interpretation is attached as Addendum A.

**2. Approval of 2012 NCAA Convention Division III Legislative Proposals Question and Answer Guide**. The committee, through consultation with staff and the sponsors of membership legislation, developed and approved the first and second editions of the Question and Answer document. The second edition is included as Supplement No. 16 of the NCAA Division III Management Council January 2012 Agenda.

**3. Election of Chair**. The committee elected Darryl Sims, Athletics Director, University of Wisconsin, Oshkosh, as chair of the committee.

*Committee Chair: Lori Runksmeier, New England College*
*Staff Liaisons: Jeff Myers, Academic and Membership Affairs*
*Kristin Nesbitt, Academic and Membership Affairs*

Interpretations

**Title:** Participation in Intercollegiate Competition by Student-Athletes Who Identify as Transgender (III)

**Date Issued:** October 26, 2011

**Date Published:** November 15, 2011

**Type:** Staff Interpretation

**Item Ref:** c

The academic and membership affairs staff determined, pursuant to policy approved by the NCAA Executive Committee, that:

(a) A trans-male student-athlete who has received a medical exception for treatment with testosterone for diagnosed Gender Identity Disorder (GID) may compete on a men's team but is no longer eligible to compete on a women's team without changing that team's status to a mixed team;

(b) A trans-female student-athlete who is being treated with testosterone suppression medication for GID may continue to compete on a men's team but may not compete on a women's team without changing that team's status to a mixed team until the student-athlete has completed one calendar year of testosterone suppression treatment;

(c) It is the responsibility of the institution to submit a request for a medical exception for testosterone treatment prior to allowing the student-athlete to compete while undergoing treatment. In the case of testosterone suppression, the institution must submit written documentation of the year of treatment and ongoing monitoring of testosterone suppression to the Committee on Competitive Safeguards and Medical Aspects of Sports; and

(d) For the purposes of NCAA competition, cases involving interruptions of GID treatment will be reviewed on a case-by-case basis by the Committee on Competitive Safeguards and Medical Aspects of Sports.

[References: NCAA Division III Bylaws 18.02.2 (mixed team), 18.2.8.3 (mixed team), 20.02.8 (mixed team) and 31.2.3.5 (medical exceptions); a staff interpretation (11/1/89, Item c) and the August 11, 2011, report of the Executive Committee.]

| **Legislative References** | | |
|---|---|---|
| **Div.** | **Number** | **Title** |
| III | 18.02.2 | Mixed Team. |
| III | 18.2.8.3 | Mixed Team. |
| III | 20.02.8 | Mixed Team. |
| III | 31.2.3.5 | Medical Exceptions. |

**References Interpretations**

| **Effective Date** | **Type** | **Summary** |
|---|---|---|
| November 1, 1989 | Staff Interpretation | Participation in mixed team championships and individual sports |



Date Printed: December 13, 2011